Bionic Pancreas in CFRD
NCT: NCT06449677 · ACTIVE_NOT_RECRUITING
Publicidade
Resumo breve
This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week study period in individuals ≥14 years old with cystic fibrosis-related diabetes (CFRD). After 13 weeks, participants will continue in a 13-week Extension Phase in which the BP group will continue to use the BP system and the Usual Care group will initiate use of the BP system.
Fonte oficial
Ver no ClinicalTrials.gov →Dados provenientes da API do ClinicalTrials.gov. Para consultar o estado mais recente, veja o registo oficial.